{"id":"W4396939418","doi":"10.1016/j.isci.2024.109978","title":"CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer","year":2024,"lang":"en","type":"article","venue":"iScience","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sierra Wireless (Canada)","funders":"Cancer Council Queensland; Cancer Council NSW; National Health and Medical Research Council; Cancer Council South Australia; Medical Research Council; Cancer Council Tasmania; National Institutes of Health; Cooperative Research Centres, Australian Government Department of Industry; Cancer Council Victoria; Eisai; Australian Centre for Geomechanics; Sierra Oncology; University of Melbourne; Clovis Oncology; BeiGene; Australian Government; Medical Research and Materiel Command; Victorian Cancer Agency; University of Pennsylvania; Johns Hopkins University; AstraZeneca","keywords":"Ovarian cancer; PARP inhibitor; Cancer research; Chemistry; Medicine; Cancer; Poly ADP ribose polymerase; Internal medicine; DNA; Biochemistry; Polymerase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001254328,0.0002010072,0.0003919052,0.0002677811,0.0001377869,0.0002193362,0.0001858802,0.0001965449,0.001154174],"category_scores_gemma":[0.00009697354,0.00009404594,0.0001767114,0.000264534,0.0001396401,0.0001559464,0.00007682382,0.0005431256,0.0001762855],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002715792,"about_ca_system_score_gemma":0.0003570619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000959182,"about_ca_topic_score_gemma":0.004136951,"domain_scores_codex":[0.9999206,0.00001758204,0.000005783815,0.00001006102,0.00002155532,0.00002430089],"domain_scores_gemma":[0.9999431,0.00001009247,0.00001376376,0.00000578035,0.000005518321,0.00002177507],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003516672,0.001148525,0.001855284,0.0002075699,0.00008509159,0.0003286687,0.00004738653,0.0008973331,0.9563941,0.0003066444,0.0008231687,0.03438962],"study_design_scores_gemma":[0.001162566,0.02766459,0.03276668,0.00002979635,0.0002187701,0.002267227,0.0001288912,0.00433398,0.9209279,0.0001652041,0.01030866,0.00002564443],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945052,0.003667822,0.0002380024,0.00008053224,0.00001819844,0.00003460723,0.0002255203,0.00004526121,0.001184726],"genre_scores_gemma":[0.9968256,0.001573092,0.0003762301,0.00003136279,0.000009306718,0.00002064908,0.0004035938,0.000006747859,0.0007535112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001154174,"threshold_uncertainty_score":0.003861129,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0326593061972015,"score_gpt":0.3409201649224782,"score_spread":0.3082608587252766,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}